JAMA Network
About The Study: During January 2016 through October 2022, the monthly buprenorphine initiation rate in the U.S. increased, then flattened. This flattening occurred prior to the COVID-19 pandemic, suggesting that factors other than the pandemic were involved.
Authors: Kao-Ping Chua, M.D., Ph.D., of the University of Michigan Medical School in Ann Arbor, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.1207)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
